Takeda has signed another AI-focused deal, this time focusing on small molecules with the San Diego biotech Iambic. The two announced the multiyear deal Monday, working on undisclosed targets in the oncology, gastrointestinal and inflammation …
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
